LEGN
$18.66-0.44 (-2.30%)
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
Intraday
Recent News
Genscript Biotech Corp (GNNSF) Full Year 2025 Earnings Call Highlights: Record Revenue Growth ...
Genscript Biotech Corp (GNNSF) reports a 61.4% revenue surge to $959.5 million, driven by strategic global expansion and key partnerships.
Legend Biotech Shares Likely to Rebound in 2026 on Robust Fundamentals, RBC Says
Legend Biotech (LEGN) shares should rebound in 2026 on robust execution of Carvykti to treat multipl
Legend Biotech (LEGN) Valuation Check After Recent Share Price Rebound And Undervalued Narrative
Legend Biotech: Stock snapshot and recent performance Legend Biotech (LEGN) has drawn investor interest after a mixed pattern of recent returns, with gains over the past month alongside weaker performance over the past 3 months and year to date. The stock last closed at US$19.56, with a 1 day return of 2.19% and a 7 day return of 9.52%. Over the past month, the share price return is 14.39%, while the past 3 months show a 16.27% decline and the year to date move stands at a 9.07% decline. See...
Legend Biotech Corp (LEGN) Q4 2025 Earnings Call Highlights: Record Growth and Profitability ...
Legend Biotech Corp (LEGN) reports a 64% revenue increase and achieves profitability, driven by strong Carvicti sales and strategic global expansion.
Legend Biotech Q4 Earnings Call Highlights
Legend Biotech (NASDAQ:LEGN) executives highlighted accelerating global demand for CARVYKTI, improving profitability metrics, and expanding manufacturing capacity during the company’s fourth quarter 2025 earnings call. Management said CARVYKTI reached profitability in 2025 and the company expects to